rais pt durabl revenu
heel strong perform rais
estim pt increas ep
pt old new
maintain ew rate
encourag growth revenu grew second highest
recent memori highest organ growth
due favor fx zoeti organ revenu growth driven
price volum volum growth driven
dermatolog product in-lin product growth came new
investor concern companion anim would slow tougher
comp growth robust global companion anim rose driven
key franchis exhibit show apoquel tablet atop dermat
dog cytopoint inject atop dermat dog simparica oral flea
 tick protect dog trend
companion anim prospect remain robust drove higher estim
anticip on-going global adopt major product addit zoeti
plan launch tripl combo line extens simparica
add heartworm protect exist simparica flea tick product
increas ep project follow
close high end guidanc rang
compound-annual-growth-rate
ep growth current vs previous
model also reflect abaxi contribut estim abaxi contribut
note latest guidanc reflect
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
inclus abaxi result last month year us month
intern abaxi annual run rate base result
abaxi recent grew yoy estim zoeti book
abaxi revenue full year assum abaxi
revenu growth yoy comment relat abaxi includ
acquisit slightli dilut earn accret
abaxi revenu us primarili companion anim space
base case ep current price-to-earnings premium vs
also roughli line w/ average sinc ipo project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast
base case ep
base case ep
project solid double-digit ep growth driven growth
companion anim livestock project compound-annual-growth-rate revenu growth
ep compound-annual-growth-rate easier us livestock comp
global roll-out new product give us confid project
bear case ep
bear case ep
face lower end-market growth greater competit pressur drive
weak financi result share trade compani miss ep estimate
price-to-earnings multipl contract
rate zoeti ow combin
improv cash flow convers tuck-in
 option drive
ep growth
top-lin growth oper margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
risk achiev price
long-term margin expans fail
new govern regul legisl
impact growth
dollar strength rel foreign
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
